Neurogene, Inc. - Common Stock NGNE 深 沪
等待开盘 07-24 09:30:00 美东时间
23.09
+1.150
+5.24%
华盛通- 最 高23.8763
- 今 开22.41
- 成交量 16.16万股
- 最 低 22.26
- 昨 收 21.94
- 总市值 3.29亿
- 52周最高 74.49
- 市盈率 静 --
- 换手率 1.13%
- 52周最低 6.875
- 委 比 0.00%
- 总股本 1426.21万
- 历史最高 362.60
- 量 比 1.43
- 振 幅 7.37%
- 历史最低 6.875
- 每 手 1
- 风险率 13.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | Wolfspeed单日暴涨98%！拟进行破产重组；BitMine公告以太坊储备计划
Wolfspeed单日暴涨98%！拟通过破产重组削减约70%的债务；BitMine隔夜大涨幅35.7%，公告以太坊储备计划>>
07-02 19:38
Neurogene shares are trading higher after the company announced details of its registrational clinical trial designed to evaluate NGN-401 gene therapy for the treatment of females with Rett syndrome in participants ages 3 years and older.
Neurogene shares are trading higher after the company announced details of its ...
07-01 22:44
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
BMO Capital Maintains Outperform on Neurogene, Raises Price Target to $26
BMO Capital analyst Evan David Seigerman maintains Neurogene (NASDAQ:NGNE) with a Outperform and raises the price target from $22 to $26.
06-12 23:00
Neurogene Highlights Gene Therapy Advancements in New Update
Neurogene ( ($NGNE) ) has provided an announcement. On June 9, 2025, Neurogene ...
06-09 19:49
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
BMO Capital Maintains Outperform on Neurogene, Raises Price Target to $22
BMO Capital analyst Keith Tapper maintains Neurogene (NASDAQ:NGNE) with a Outperform and raises the price target from $16 to $22.
05-20 21:03
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
